MYGN: New cancer-focused strategy and product launches set stage for strong growth in 2026

What Happened?

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Therapeutics company Myriad Genetics jumped 4.8%. Is now the time to buy Myriad Genetics? Access our full analysis report here, it’s free for active Edge members.
• Medical Devices & Supplies - Diversified company Neogen jumped 4.3%. Is now the time to buy Neogen? Access our full analysis report here, it’s free for active Edge members.
• Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical jumped 4.6%. Is now the time to buy ICU Medical? Access our full analysis report here, it’s free for active Edge members.
• Hospital Chains company HCA Healthcare jumped 3.1%. Is now the time to buy HCA Healthcare? Access our full analysis report here, it’s free for active Edge members.
• Hospital Chains company Universal Health Services jumped 2.8%. Is now the time to buy Universal Health Services? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Myriad Genetics (MYGN)

Myriad Genetics’s shares are extremely volatile and have had 43 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock gained 7.2% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

Myriad Genetics is down 42.8% since the beginning of the year, and at $7.73 per share, it is trading 53.7% below its 52-week high of $16.69 from December 2024. Investors who bought $1,000 worth of Myriad Genetics’s shares 5 years ago would now be looking at an investment worth $424.22.